Anil Varma V Vatsavayi1, Julia Kofler2, Mary Ann A Demichele-Sweet3, Patrick S Murray1, Oscar L Lopez3, Robert A Sweet1. 1. Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 2. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 3. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Abstract
BACKGROUND: TAR DNA-binding protein 43 (TDP-43) has been identified as a major disease protein in frontotemporal lobar degeneration. More recently, TDP-43 proteinopathy has also been observed in Alzheimer's disease (AD) with a characteristic distribution of TDP-43 predominantly in the mesial temporal lobe, and to a lesser degree in the neocortical areas. AD subjects with psychotic symptoms (AD+P) represent a subgroup characterized by greater impairment of frontal cortex-dependent cognitive functions and more severe frontal cortical neuropathology. The aim of this study is to determine whether there is an association between TDP-43 pathology and AD+P. We hypothesized that TDP-43 pathology would be more frequent in AD+P than in AD without psychosis. METHODS: We studied the presence and distribution of TDP-43 pathology by immunohistochemistry in the dentate gyrus (DG) and prefrontal cortex (FC) of postmortem brain specimens from 68 subjects with a primary neuropathologic diagnosis of AD as determined by the Neuropathology Core of the University of Pittsburgh Alzheimer's Disease Research Center. RESULTS: Forty-five (66%) subjects were classified as AD+P. Fourteen (20.6%) subjects had TDP-43 pathology in DG, eight (11.8%) had TDP-43 pathology in FC, and six (8.8%) had TDP-43 pathology in both regions. TDP-43 in DG was not significantly associated with AD+P. However, TDP-43 in FC demonstrated a trend toward reduced likelihood of psychosis (p = 0.068). TDP-43 pathology in DG, but not FC, was significantly associated with greater age at death and longer duration of illness. CONCLUSIONS: Our findings indicate that there was no association between concomitant TDP-43 pathology in DG or FC and AD+P.
BACKGROUND:TAR DNA-binding protein 43 (TDP-43) has been identified as a major disease protein in frontotemporal lobar degeneration. More recently, TDP-43 proteinopathy has also been observed in Alzheimer's disease (AD) with a characteristic distribution of TDP-43 predominantly in the mesial temporal lobe, and to a lesser degree in the neocortical areas. AD subjects with psychotic symptoms (AD+P) represent a subgroup characterized by greater impairment of frontal cortex-dependent cognitive functions and more severe frontal cortical neuropathology. The aim of this study is to determine whether there is an association between TDP-43 pathology and AD+P. We hypothesized that TDP-43 pathology would be more frequent in AD+P than in AD without psychosis. METHODS: We studied the presence and distribution of TDP-43 pathology by immunohistochemistry in the dentate gyrus (DG) and prefrontal cortex (FC) of postmortem brain specimens from 68 subjects with a primary neuropathologic diagnosis of AD as determined by the Neuropathology Core of the University of Pittsburgh Alzheimer's Disease Research Center. RESULTS: Forty-five (66%) subjects were classified as AD+P. Fourteen (20.6%) subjects had TDP-43 pathology in DG, eight (11.8%) had TDP-43 pathology in FC, and six (8.8%) had TDP-43 pathology in both regions. TDP-43 in DG was not significantly associated with AD+P. However, TDP-43 in FC demonstrated a trend toward reduced likelihood of psychosis (p = 0.068). TDP-43 pathology in DG, but not FC, was significantly associated with greater age at death and longer duration of illness. CONCLUSIONS: Our findings indicate that there was no association between concomitant TDP-43 pathology in DG or FC and AD+P.
Authors: R A Sweet; R L Hamilton; O L Lopez; W E Klunk; S R Wisniewski; D I Kaufer; M T Healy; S T DeKosky Journal: Int Psychogeriatr Date: 2000-12 Impact factor: 3.878
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: R A Sweet; B G Pollock; D L Sukonick; B H Mulsant; J Rosen; W E Klunk; K B Kastango; S T DeKosky; R E Ferrell Journal: Int Psychogeriatr Date: 2001-12 Impact factor: 3.878
Authors: Robert A Sweet; Kanagasabai Panchalingam; Jay W Pettegrew; Richard J McClure; Ronald L Hamilton; Oscar L Lopez; Daniel I Kaufer; Steven T DeKosky; William E Klunk Journal: Neurobiol Aging Date: 2002 Jul-Aug Impact factor: 4.673
Authors: Caitlin M Kirkwood; Matthew L MacDonald; Tadhg A Schempf; Anil V Vatsavayi; Milos D Ikonomovic; Jeremy L Koppel; Ying Ding; Mai Sun; Julia K Kofler; Oscar L Lopez; Nathan A Yates; Robert A Sweet Journal: J Neuropathol Exp Neurol Date: 2016-02 Impact factor: 3.685
Authors: Peter T Nelson; Dennis W Dickson; John Q Trojanowski; Clifford R Jack; Patricia A Boyle; Konstantinos Arfanakis; Rosa Rademakers; Irina Alafuzoff; Johannes Attems; Carol Brayne; Ian T S Coyle-Gilchrist; Helena C Chui; David W Fardo; Margaret E Flanagan; Glenda Halliday; Suvi R K Hokkanen; Sally Hunter; Gregory A Jicha; Yuriko Katsumata; Claudia H Kawas; C Dirk Keene; Gabor G Kovacs; Walter A Kukull; Allan I Levey; Nazanin Makkinejad; Thomas J Montine; Shigeo Murayama; Melissa E Murray; Sukriti Nag; Robert A Rissman; William W Seeley; Reisa A Sperling; Charles L White; Lei Yu; Julie A Schneider Journal: Brain Date: 2019-06-01 Impact factor: 15.255
Authors: Oscar L Lopez; Julia Kofler; YueFang Chang; Sarah B Berman; James T Becker; Robert A Sweet; Neelesh Nadkarni; Riddhi Patira; M Ilyas Kamboh; Ann D Cohen; Beth E Snitz; Lewis H Kuller; William E Klunk Journal: Ann Clin Transl Neurol Date: 2020-07-31 Impact factor: 4.511